Principal Financial Group Inc. boosted its position in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 190,845 shares of the biopharmaceutical company’s stock after acquiring an additional 2,712 shares during the quarter. Principal Financial Group Inc. owned 0.41% of Sucampo Pharmaceuticals worth $2,004,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of SCMP. Great West Life Assurance Co. Can increased its position in Sucampo Pharmaceuticals by 900.8% during the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 32,203 shares during the last quarter. Bank of New York Mellon Corp increased its position in Sucampo Pharmaceuticals by 107.3% during the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock valued at $4,044,000 after acquiring an additional 190,292 shares during the last quarter. Comerica Bank purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $275,000. Karp Capital Management Corp purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $119,000. Finally, Texas Permanent School Fund purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $197,000. Institutional investors own 55.44% of the company’s stock.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 10.525 on Friday. Sucampo Pharmaceuticals, Inc. has a 12-month low of $9.30 and a 12-month high of $17.55. The firm’s 50-day moving average price is $11.70 and its 200 day moving average price is $10.73. The company’s market cap is $487.57 million.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. The company had revenue of $59.90 million during the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the business posted $0.24 EPS. On average, analysts predict that Sucampo Pharmaceuticals, Inc. will post $1.01 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/08/principal-financial-group-inc-boosts-position-in-sucampo-pharmaceuticals-inc-scmp.html.

SCMP has been the subject of a number of research reports. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Maxim Group set a $23.00 price objective on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. TheStreet cut Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Finally, Roth Capital set a $30.00 price objective on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.86.

In related news, insider Jones W. Bryan acquired 4,700 shares of Sucampo Pharmaceuticals stock in a transaction on Friday, August 4th. The stock was acquired at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the purchase, the insider now owns 4,700 shares of the company’s stock, valued at approximately $49,820. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.